News | EP Lab | December 10, 2018

Technology Improvements Driving Electrophysiology Market Growth

Success of device therapies over traditional pharmaceutical approaches expected to promote major market growth worldwide

Technology Improvements Driving Electrophysiology Market Growth

Navik 3D Cardiac Mapping System image courtesy of APN Health.

December 10, 2018 — Electrophysiology, while currently a relatively small market at $4.6 billion in 2018, has recently become of great interest in the medical devices field, with the market expected to reach $8.5 billion by 2023, according to GlobalData. This would represent a compound annual growth rate (CAGR) of 4.6 percent.

Interest in electrophysiology has grown as technological advancements such as live 3-D mapping and location have allowed doctors to more easily and effectively identify and ablate troublesome material. This has shortened procedure times, meaning that patients have shorter recovery times as well. This has resulted in a huge spike in growth of electrophysiology treatments at the expense of pharmacological treatments. In particular, the growth of the MEA and Latin America regions are larger at 5.6-5.7 percent year over year, due to their relatively undeveloped healthcare systems only now beginning to adopt electrophysiological technology.

James Spencer, medical devices analyst at GlobalData, commented, “Electrophysiology is uniquely positioned amongst cardiovascular devices to enjoy both explosive and sustained growth across the international markets due to a combination of as yet unsaturated markets, the cannibalization of revenue from less effective pharmacological treatments, as well as a constantly growing patient population due to the overall aging of the world’s population.”

Traditionally, electrophysiology catheters have used radiofrequency (RF) ablation techniques to ablate troublesome tissue. However, more recently, cryoablative and laser ablation technologies have been developed that are easier or more effective for physicians to use. As such, the electrophysiology market is now in a favorable position for years to come, according to GlobalData.

For more information: www.globaldata.com

Related Content

Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
Overlay Init